Novo Nordisk(US:NVO)2024-09-30 11:57Share Repurchase Program - Novo Nordisk initiated a share repurchase program on August 7, 2024, with a total budget of up to DKK 20 billion over a 12-month period starting February 6, 2024[2][7] - As of September 27, 2024, Novo Nordisk has repurchased a total of 12,671,184 B shares at an average price of DKK 880.84, amounting to a transaction value of DKK 11,161,264,179[7] - The company has accumulated 1,604,058 B shares under the repurchase program, with a total transaction value of DKK 1,433,558,129 since the last announcement[4][7] - Novo Nordisk currently holds 13,999,815 B shares as treasury shares, representing 0.3% of the total share capital[6] - The average purchase price for the shares repurchased since the program's initiation is DKK 805.09[4] - The share repurchase program is part of Novo Nordisk's strategy to enhance shareholder value and return capital to shareholders[2] Company Overview - Novo Nordisk employs approximately 69,000 people and markets its products in around 170 countries, indicating a strong global presence[8] - The company is listed on Nasdaq Copenhagen and its ADRs are traded on the New York Stock Exchange, enhancing its visibility in international markets[8] Commitment to Healthcare - Novo Nordisk's commitment to driving change in healthcare is reflected in its ongoing investments in scientific breakthroughs and expanding access to medicines[8] - The company continues to focus on chronic disease management, particularly in diabetes, aligning its business strategy with its heritage[8]